This test is most useful if any of these apply to you.
If you have unexplained episodes of pounding heartbeat, sweating, headaches, or blood pressure spikes that come and go, the cause may not show up on a standard physical or routine lab panel. A urine test for VMA (vanillylmandelic acid) looks for chemical evidence that your adrenal glands or nerve tissue are pumping out unusually high amounts of stress hormones, sometimes from a small, treatable tumor that has been hiding for years.
VMA is a long-used marker for catecholamine-secreting tumors like pheochromocytoma, and it also gives a window into your overall sympathetic (fight-or-flight) nervous system activity. It is not a routine wellness number to chase week to week. It is a targeted question: are stress chemicals in your body running higher than they should?
Your adrenal glands (small organs on top of your kidneys) and your sympathetic nerve endings produce two stress chemicals: adrenaline (epinephrine) and noradrenaline (norepinephrine). After these chemicals do their job, your liver processes them into smaller breakdown products. VMA is one of those final products, and it exits the body in urine.
Because most of the adrenaline and noradrenaline your body makes ends up as VMA in urine, this single measurement reflects the overall pace of your stress-hormone production. The more catecholamines your tissues are pumping out, the more VMA your kidneys excrete.
The biggest reason to know your VMA level is to detect tumors that produce catecholamines on their own, independent of normal nervous system control. These tumors can cause severe, episodic high blood pressure and serious cardiovascular complications, but they are surgically curable if caught early.
In a study of 159 adults investigated for pheochromocytoma (a rare adrenal tumor), 24-hour urinary VMA correctly identified about 63 out of 100 people with the tumor and correctly cleared about 94 out of 100 people without it. A clearly elevated VMA is meaningful, but a normal VMA does not fully rule the tumor out. A separate test called urinary or plasma metanephrines is more sensitive and is now the preferred first-line screen, which is why VMA is often ordered alongside metanephrines rather than alone.
In children with neuroblastoma (a nerve-tissue tumor), urinary VMA combined with a related metabolite (HVA) detects most cases. Adding a broader panel of eight catecholamine breakdown products raises detection to about 95 out of 100. VMA levels also track tumor activity over time and have been used to predict recurrence when combined with serum CA125 and NSE (other tumor markers).
Beyond tumors, VMA reflects how hard your sympathetic nervous system is working. After a heart attack, urinary VMA rises sharply and correlates with low blood pressure, heart failure, and dangerous heart rhythms, signaling massive adrenaline release. Many people with essential (no-known-cause) high blood pressure also show urinary VMA above age-matched upper limits, though the elevation appears to be a consequence of the elevated pressure rather than its root cause.
What this means for you: if you have persistent or paroxysmal high blood pressure that resists standard treatment, a VMA test, ideally alongside metanephrines, can help determine whether overactive catecholamine production is part of the picture rather than just garden-variety hypertension.
VMA also moves with environmental exposures. In a cross-sectional study of 696 adults, higher exposure to volatile organic compounds (common indoor air pollutants from solvents, paints, and fuels) was linked to higher urinary VMA, consistent with chronic low-grade sympathetic activation. Exposure to coarse air particles also shifted VMA in a controlled crossover trial. These findings suggest VMA can pick up environmentally driven stress responses that may, over time, contribute to cardiovascular risk.
Reduced urinary VMA usually points to dampened sympathetic outflow. In a study of severely obese patients with craniopharyngioma (a tumor that damages the hypothalamus), urinary VMA and HVA were significantly lower than in healthy controls, reflecting blunted sympathetic activity that contributed to reduced physical activity and weight gain. Outside of specific neurological injury, persistently low VMA is uncommon and rarely the reason for testing.
A single VMA reading captures one snapshot of catecholamine output. Stress hormones swing throughout the day and respond to acute illness, exercise, recent meals, and emotional state. That biological variability is exactly why serial trending matters more than any one number, especially if you are monitoring response to treatment or trying to detect a slow-growing tumor that may not push VMA above the standard upper limit on day one.
A reasonable approach: get a baseline measurement, repeat in 3 to 6 months if you are making lifestyle changes or starting medications that affect sympathetic activity, and then annually if values stay stable. If you are being monitored after surgical removal of a catecholamine-secreting tumor, follow your specialist's schedule, which is typically more frequent in the first year and then at least yearly thereafter.
VMA testing has several well-documented confounders that can produce a misleading single reading. Knowing them protects you from acting on a false alarm or being falsely reassured.
If your VMA comes back clearly elevated, the next step is not panic. It is a targeted workup. The most important companion test is urinary or plasma fractionated metanephrines, which are more sensitive than VMA for pheochromocytoma and paraganglioma. If both are elevated, an endocrinologist will typically arrange imaging of the adrenal glands and along the sympathetic chain to look for a tumor. A mildly elevated VMA with normal metanephrines, no symptoms, and an obvious dietary or stress confounder is usually a cue to repeat the test under cleaner conditions before pursuing further investigation.
If symptoms point strongly toward a catecholamine excess but VMA is normal, do not stop there. A meaningful fraction of catecholamine-secreting tumors can have normal VMA, which is why metanephrines and broader catecholamine panels are now preferred when clinical suspicion is high.
Evidence-backed interventions that affect your Vanillylmandelic Acid (VMA) level
Vanillylmandelic Acid (VMA) is best interpreted alongside these tests.
Vanillylmandelic Acid (VMA) is included in these pre-built panels.